{"id":"W2483350877","doi":"10.1182/blood.v126.23.1742.1742","title":"A Phase 2 Study of Ofatumumab in Combination with a Pan-AKT Inhibitor (Afuresertib) in Previously Treated Patients with Chronic Lymphocytic Leukemia (CLL)","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada); CancerCare Manitoba; Princess Margaret Cancer Centre","funders":"","keywords":"Ofatumumab; Medicine; Fludarabine; Internal medicine; Chronic lymphocytic leukemia; Refractory (planetary science); Regimen; Gastroenterology; Neutropenia; Phases of clinical research; Pharmacodynamics; Oncology; Pharmacology; Pharmacokinetics; Leukemia; Clinical trial; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002474136,0.002002427,0.002629051,0.0005326201,0.0006674649,0.001131775,0.0009023516,0.001265225,0.003656972],"category_scores_gemma":[0.001039095,0.001089138,0.002029105,0.0004896027,0.001271166,0.001037274,0.000553325,0.00368468,0.0008909557],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001107396,"about_ca_system_score_gemma":0.001858259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001441915,"about_ca_topic_score_gemma":0.002877775,"domain_scores_codex":[0.9992803,0.0003441333,0.00003733082,0.0001219386,0.00005640728,0.0001598962],"domain_scores_gemma":[0.9990459,0.0001717575,0.0001466234,0.00009509335,0.00005559169,0.0004850415],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7154229,0.1349433,0.01091126,0.0007757299,0.001675275,0.0008498161,0.0006720073,0.002253386,0.06791008,0.000255176,0.002398074,0.06193287],"study_design_scores_gemma":[0.4407398,0.5426962,0.01048611,0.00002078327,0.0004248542,0.0003782815,0.00006032962,0.0006557271,0.002797445,0.00008079241,0.001628478,0.00003137641],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956315,0.001162889,0.0003049957,0.0002678158,0.00008655707,0.0014821,0.0003515,0.00003764379,0.0006751407],"genre_scores_gemma":[0.9908711,0.001316459,0.001226505,0.0005296236,0.0002563544,0.002534935,0.00136802,0.00002287068,0.001874145],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003656972,"threshold_uncertainty_score":0.01308459,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01830524461602995,"score_gpt":0.28747154493414,"score_spread":0.2691663003181101,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}